Droxidopa-13C2,15N hydrochloride
Modify Date: 2024-01-11 16:43:46
Droxidopa-13C2,15N hydrochloride structure
|
Common Name | Droxidopa-13C2,15N hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1329556-63-9 | Molecular Weight | 252.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C713C2H12Cl15NO5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Droxidopa-13C2,15N hydrochlorideDroxidopa-13C2,15N (hydrochloride) is deuterium labeled Droxidopa. Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood–brain barrier[1][2]. |
| Name | Droxidopa-13C2,15N hydrochloride |
|---|
| Description | Droxidopa-13C2,15N (hydrochloride) is deuterium labeled Droxidopa. Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood–brain barrier[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References |
| Molecular Formula | C713C2H12Cl15NO5 |
|---|---|
| Molecular Weight | 252.63 |